Augmented osteolysis in SPARC-deficient mice with bone residing prostate cancer

Neoplasia

Volumn 13, Issue 1, 2011, Pages 31-39

  McCabe, N Patrick ^a   Kerr, Bethany A ^a   Madajka, Maria ^a   Vasanji, Amit ^a   Byzova, Tatiana V ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; OSTEONECTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE METASTASIS; CANCER CELL; CANCER GROWTH; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; IN VITRO STUDY; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOMETRY; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 78650967989     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10998     Document Type: Article

References (35)

1. Coleman RE (1997). Skeletal complications of malignancy. Cancer 80, 1588-1594.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008). Cancer statistics, 2008. CA Cancer J Clin 58, 71-96.
3. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, et al. (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101, 811-816.
4. Thomas R, True LD, Bassuk JA, Lange PH, and Vessella RL (2000). Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 6, 1140-1149.
5. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, and Chinnaiyan AM (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826.
6. Brekken RA and Sage EH (2000). SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 19, 816-827.
7. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, and Llera AS (2008). The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 27, 691-705.
8. Jacob K, Webber M, Benayahu D, and Kleinman HK (1999). Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res 59, 4453-4457.
9. Wang Y, Yu Q, Cho AH, Rondeau G, Welsh J, Adamson E, Mercola D, and McClelland M (2005). Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia 7, 748-760.
10. Wong SY, Crowley D, Bronson RT, and Hynes RO (2008). Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer. Clin Exp Metastasis 25, 109-118.
11. Said N, Frierson HF Jr, Chernauskas D, Conaway M, Motamed K, and Theodorescu D (2009). The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene 28, 3487-3498.
12. De S, Chen J, Narizhneva NV, Heston W, Brainard J, Sage EH, and Byzova TV (2003). Molecular pathway for cancer metastasis to bone. J Biol Chem 278, 39044-39050.
13. Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, Logothetis CJ, and Lin SH (2007). A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res 67, 6544-6548.
14. Kwabi-Addo B, Wang S, Chung W, Jelinek J, Patierno SR,Wang BD, Andrawis R, Lee NH, Apprey V, Issa JP, et al. (2010). Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res 16, 3539-3547.
15. Podgorski I, Linebaugh BE, Koblinski JE, Rudy DL, Herroon MK, Olive MB, and Sloane BF (2009). Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. Am J Pathol 175, 1255-1269.
16. Norose K, Clark JI, Syed NA, Basu A, Heber-Katz E, Sage EH, and Howe CC (1998). SPARC deficiency leads to early-onset cataractogenesis. Invest Ophthalmol Vis Sci 39, 2674-2680.
17. McCabe NP, Madajka M, Vasanji A, and Byzova TV (2008). Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition. Clin Exp Metastasis 25, 581-590.
18. Hildebrand T, Laib A, Muller R, Dequeker J, and Ruegsegger P (1999). Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 14, 1167-1174.
19. Delany AM, Amling M, Priemel M, Howe C, Baron R, and Canalis E (2000). Osteopenia and decreased bone formation in osteonectin-deficient mice. J Clin Invest 105, 915-923.
20. Roato I, D'Amelio P, Gorassini E, Grimaldi A, Bonello L, Fiori C, Delsedime L, Tizzani A, De Libero A, Isaia G, et al. (2008). Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS ONE 3, e3627.
21. American Cancer Society (2008). Melanoma Skin Cancer. American Cancer Society, Atlanta, GA.
22. American Cancer Society (2008). Prostate Cancer. American Cancer Society, Atlanta, GA.
23. Power CA, Pwint H, Chan J, Cho J, Yu Y, Walsh W, and Russell PJ (2009). A novel model of bone-metastatic prostate cancer in immunocompetent mice. Prostate 69, 1613-1623.
24. Tourkova IL, Yamabe K, Chatta G, Shurin GV, and Shurin MR (2003). NK cells mediate Flt3 ligand-induced protection of dendritic cell precursors in vivo from the inhibition by prostate carcinoma in the murine bone marrow metastasis model. J Immunother 26, 468-472.
25. Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, Engbring JA, Wang S, Goldsmith CM, Piper JT, Vostal JG, Harms JF, et al. (2005). Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res 65, 7370-7377.
26. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, and McCauley LK (2005). Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146, 1727-1736.
27. Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, and Athanasou NA (1996). The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 137, 4058-4060.
28. Teitelbaum SL (2000). Bone resorption by osteoclasts. Science 289, 1504-1508.
29. Machado do Reis L, Kessler CB, Adams DJ, Lorenzo J, Jorgetti V, and Delany AM (2008). Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice. Bone 43, 264-273.
30. Brubaker KD, Vessella RL, True LD, Thomas R, and Corey E (2003). Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 18, 222-230.
31. Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, and Sage EH (2003). Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest 111, 487-495.
32. Puolakkainen PA, Brekken RA, Muneer S, and Sage EH (2004). Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2, 215-224.
33. Said N and Motamed K (2005). Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 167, 1739-1752.
34. Boskey AL, Moore DJ, Amling M, Canalis E, and Delany AM (2003). Infrared analysis of the mineral and matrix in bones of osteonectin-null mice and their wild type controls. J Bone Miner Res 18, 1005-1011.
35. Trombetta JM and Bradshaw AD (2010). SPARC/osteonectin functions to maintain homeostasis of the collagenous extracellular matrix in the periodontal ligament. J Histochem Cytochem 58, 871-879.